Yousuke Aoki

CT imaging features associated with recurrence in non-small cell lung cancer patients after stereotactic body radiotherapy

Etoposide: four decades of development of a topoisomerase II inhibitor

Management of early-stage non-small cell lung cancer using stereotactic ablative radiotherapy: Controversies, insights, and changing horizons

Hepatocellular carcinoma

Hepatocellular carcinoma

A global view of hepatocellular carcinoma: trends, risk, prevention and management

BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update

Machine Learning methods for Quantitative Radiomic Biomarkers

Stereotactic Ablative Radiotherapy for Centrally Located Early Stage Non–Small-Cell Lung Cancer: What We Have Learned

Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Treatment and Prognosis of Isolated Local Relapse after Stereotactic Body Radiotherapy for Clinical Stage I Non-Small-Cell Lung Cancer

Promises and challenges for the implementation of computational medical imaging (radiomics) in oncology

Role of radiotherapy in the management of hepatocellular carcinoma: A systematic review

Bioavailability of low-dose oral etoposide.

The effect of SUV discretization in quantitative FDG-PET Radiomics: the need for standardized methodology in tumor texture analysis

British Thoracic Society guidelines for the investigation and management of pulmonary nodules: accredited by NICE

Consensus on Stereotactic Body Radiation Therapy for Small-Sized Hepatocellular Carcinoma at the 7th Asia-Pacific Primary Liver Cancer Expert Meeting

Curative Irradiation Treatment of Hepatocellular Carcinoma: A Multicenter Phase 2 Trial

Comparison of Stereotactic Body Radiation Therapy and Transarterial Chemoembolization for Unresectable Medium-Sized Hepatocellular Carcinoma

External Beam Radiation Therapy for Primary Liver Cancers: An ASTRO Clinical Practice Guideline

Radiomics: the bridge between medical imaging and personalized medicine

Hepatocellular carcinoma

Stability of FDG-PET Radiomics features: An integrated analysis of test-retest and inter-observer variability

Artificial intelligence in cancer imaging: Clinical challenges and applications

Safety and Efficacy of Irreversible Electroporation for the Treatment of Hepatocellular Carcinoma Not Amenable to Thermal Ablation Techniques: A Retrospective Single-Center Case Series

Radiotherapy for Hepatocellular Carcinoma Results in Comparable Survival to Radiofrequency Ablation: A Propensity Score Analysis

Stereotactic ablative radiotherapy for hepatocellular carcinoma: A systematic review and meta‐analysis of local control, survival and toxicity outcomes

EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma

Acceptable Toxicity After Stereotactic Body Radiation Therapy for Liver Tumors Adjacent to the Central Biliary System

Maximum Standardized Uptake Value on FDG-PET Is a Strong Predictor of Overall and Disease-Free Survival for Non–Small-Cell Lung Cancer Patients after Stereotactic Body Radiotherapy

The maximum standardized uptake value (SUVmax) on FDG-PET is a strong predictor of local recurrence for localized non-small-cell lung cancer after stereotactic body radiotherapy (SBRT)

Dose volume histogram analysis of focal liver reaction in follow-up multiphasic CT following stereotactic body radiotherapy for small hepatocellular carcinoma

Stereotactic body radiotherapy (SBRT) for solitary pulmonary nodules clinically diagnosed as lung cancer with no pathological confirmation: Comparison with non-small-cell lung cancer

Clinical Pharmacology and Toxicity of Low Daily Administration of Oral Etoposide in Advanced Lung Cancer Patients

Toxicities of Organs at Risk in the Mediastinal and Hilar Regions Following Stereotactic Body Radiotherapy for Centrally Located Lung Tumors

Evaluation for local failure by 18F-FDG PET/CT in comparison with CT findings after stereotactic body radiotherapy (SBRT) for localized non-small-cell lung cancer

Phase 2 study of stereotactic body radiotherapy and optional transarterial chemoembolization for solitary hepatocellular carcinoma not amenable to resection and radiofrequency ablation